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EDITORIALS
NSAIDs Without a Prescription:
Over-the-Counter Access,
Under-Counted Risks
The introduction of anti-inflammatory agents with a lower
propensity for GI injury (coxibs) has focused attention on
the well-recognized association between prescription non-
steroidal anti-inflammatory drugs (NSAIDs) and GI adverse
events. Although over-the-counter (OTC) NSAIDs—in-
cluding aspirin—are used far more frequently that their
prescription counterparts, similar notice has not been paid to
their potential health hazards. The Food and Drug Admin-
istration approval of low-dose NSAIDs to be sold without a
prescription, the long-standing availability of aspirin, and
aggressive direct-to-consumer marketing contribute to the
lay public’s perception of the safety of these drugs. Al-
though data on the GI risks of OTC NSAIDs are emerging,
most regular NSAID users lack awareness of their potential
side effects (1). The sheer numbers of individuals exposed
to OTC agents raise concern regarding their appropriate use.
Published case series have implicated OTC NSAIDs in
over one third of patients admitted for GI hemorrhage (2).
However, there is a dearth of information regarding the
effects of less serious GI adverse events attributable to these
drugs as they occur in the “real world.” Thomas et al., in this
issue of the Journal (3), report the results of a nationwide
telephone survey undertaken to evaluate indications for reg-
ular OTC NSAID use, the impact of NSAID use on GI
symptoms, and treatment patterns for these GI complaints.
The principal findings, that individuals who regularly use
OTC NSAIDs are twice as likely to report GI symptoms and
use OTC GI medications than matched controls who did not
use these drugs, are important contributions. These results
demonstrate that the well-described, “shadow costs” of
treating drug-related GI effects of prescription NSAIDs (4)
extends to the OTC sector. More importantly, it exposes the
fact that the OTC GI medications used by the study popu-
lation for their GI symptoms may effectively treat symptoms,
but do not reduce the risk of clinically meaningful adverse
events.
Antacids and histamine-2 receptor antagonists at OTC
doses may reduce dyspepsia, but have not been demon-
strated to reduce serious ulcer risk (5). Interestingly, despite
a 2-fold increased risk of symptoms and the use of GI OTC
medications by the survey respondents using OTC NSAIDs,
there was no increase in provider visits and/or GI prescrip-
tion medications compared with nonusers. These observa-
tions provide insight into the seemingly paradoxical obser-
vations from the ARAMIS database that found that
rheumatoid arthritis patients receiving prescription hista-
mine-2 receptor antagonists had increased rates of NSAID-
related ulcer disease (6). The use of medications that reduce
symptoms but do not lower ulcer risk, coupled with the fact
that these patients may not present to a clinician, may
explain this unexpected rise in adverse events in the cohort
of patients taking histamine-2 receptor antagonists.
The Thomas et al. (3) study found that aspirin or aspirin-
containing products were the predominant OTC NSAID
product used (55% of users). Low-dose aspirin, which pro-
vides unequivocal benefit for the secondary prevention of
cardiovascular (CV) disease, has been associated with a
2–4-fold increased risk of GI bleeding (7). Other studies
have established that neither enteric coating nor the use of
buffering alters this risk (8). Although the dose of aspirin for
secondary prevention of CV events varies by indication, the
dose required for most atherosclerotic complications is
likely 81 mg daily or less. Although it appears that dose
reduction is unlikely to reduce the CV protective effect of
aspirin, the evidence suggests that bleeding complications
(including GI bleeding) increase with aspirin dose (9).
These well-documented GI safety concerns of aspirin led
the U.S. Preventative Services Task Force to recommend a
risk-benefit calculation be performed before the recommen-
dation of low-dose aspirin for primary prevention of CV
events (10). They concluded that the balance of risk and
benefit of aspirin was strongly tied to cardiac risk, ex-
plicitly recommending prophylactic aspirin only to those
with a 5-yr risk of CV events 3%. Given this narrow
therapeutic window, it is clear that a clinician’s input is
warranted before beginning aspirin for primary CV pro-
phylaxis.
Nearly half (43%) of the regular NSAID users in the
Thomas et al. (3) study reported they were taking the drugs
for CV protection. The specific agents used for this indica-
tion were not provided in the manuscript. It is essential to
determine which agent(s) is being taken for cardioprotec-
tion and whether other NSAIDs are being used concur-
rently. This inquiry is critical for several reasons. First, there
is no definitive evidence that nonaspirin NSAIDs (as a class)
reduce CV events (11). Until controlled investigations de-
termine that specific traditional NSAIDs reduce the risk of
CV events to the same extent as aspirin, low-dose aspirin—
not nonaspirin NSAIDs—should be used for this indication.
Second, the risk of GI events rises substantially when more
than one NSAID is used (12). Last, it has been recently
reported that certain NSAIDs can block the antiplatelet
action of aspirin and potentially abrogate its cardioprotec-
tive properties (13). In light of these issues, we strongly
concur with the authors’ recommendation that clinicians
aggressively solicit OTC medication use and consider this
information when prescribing therapy (3).
One additional reason to query for regular aspirin use is
fueled by the ongoing debate whether the GI safety advan-
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tage of coxibs (compared with traditional NSAIDs) is re-
duced or eliminated in the setting of concomitant low-dose
aspirin. Post hoc analyses of the 21% of patients enrolled in
the CLASS trial (14) who used low-dose aspirin suggest that
the GI safety advantage of celecoxib was nearly eliminated
in the setting of aspirin cotherapy. These analyses—al-
though not appropriately powered to make a statistical in-
fererence—call into question the incremental value of
coxibs when low-dose aspirin is concomitantly prescribed
(14). In response to these data (in part), the Department
of Veterans Affairs has restricted coxib use for patients
taking aspirin (15). Ironically, the highly publicized find-
ing that coxib users may have an enhanced risk of pro-
thrombotic events has led to an increase in the use of
aspirin by individuals using coxibs for whom cardiopro-
phylaxis is indicated (16). This unexpected turn of events
mandates the performance of a well-designed GI safety
study of coxibs and aspirin before coxib use is inappro-
priately curtailed (mainly because of economic concerns)
in large populations who may benefit from less GI toxic
NSAID therapy.
Aspirin and NSAIDs have received attention in the lay
press as a potential preventive agent for certain types of
cancer and Alzheimer’s disease. These interesting yet un-
proven hypotheses may further stimulate patients to use
these agents without consulting a physician. In the case of
colon cancer prevention, the use of aspirin as either a sub-
stitute or adjunct to current screening practices cannot be
advocated either on clinical or economic grounds (17).
Thus, the decision to use these agents for chemoprevention,
as for CV prophylaxis, should be guided by a careful con-
sideration of all the risks and benefits, as well as examina-
tion of available alternative strategies.
One important missing piece of the puzzle is whether
OTC NSAID use leads to increased rates of clinically sig-
nificant adverse events. This hypothesis, although not
proven by the Thomas et al. (3) study, is supported in the
literature by case-control studies implicating OTC NSAID
doses as important risk factors for serious GI events (18).
Mechanistically, the finding of a dose-dependent relation-
ship would not be surprising because NSAID GI toxicity is
linked to inhibition of both cycloxygenase isoforms impor-
tant in maintaining upper GI mucosal defense and repair.
Preliminary data from the American College of Gastroen-
terology GI bleeding registry demonstrated OTC NSAID
use was nearly three times more common among patients
who bled when compared with controls (19).
Although the lower doses of OTC NSAIDs may be per-
ceived as safer than their prescription counterparts, their
unregulated nature does not allow control over who uses
these drugs, how much they use, and with which other
drugs. It is apparent that the clinical and economic attrac-
tiveness of available NSAID treatment options is deter-
mined by the particular NSAID used, other medications
used simultaneously, and the patients’ underlying risk for
adverse events (20). Outcomes studies that quantify the risks
and benefits of these easily accessed and widely used drugs
in different patient populations are clearly needed.
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Where Next With Endoscopic Ulcer
Hemostasis?
Severe upper GI (UGI) bleeding is a relatively frequent
reason for hospital admission in adult patients (1). In most
major medical centers, peptic ulcers are still the most com-
mon etiology for UGI hemorrhage (2, 3). However, in North
America and some European countries, ulcers are becoming
less prevalent as the cause of UGI hemorrhage than varices,
tumors, Mallory Weiss tears, and angiomas. This may relate
to primary prophylaxis (such as eradication of Helicobacter
pylori) or secondary prophylaxis in high-risk patients such
as those with a prior history of ulcer hemorrhage or those
taking nonsteroidal anti-inflammatory drugs or aspirin (4).
After initial resuscitation of patients with severe UGI
bleeding and initiation of medical therapy for those with
suspected ulcer hemorrhage, urgent endoscopy is the stan-
dard of care for diagnosis and, along with clinical history
and laboratory tests, for triaging patients by low and high
risk. Also, endoscopic treatment of those with major stig-
mata of ulcer hemorrhage (active bleeding, nonbleeding
visible vessel [NBVV], or an adherent clot) is highly rec-
ommended because outcomes improve (1–3). Oozing bleed-
ing without another stigmata (such as a NBVV or clot) is
often self-limited and does not usually require endoscopic
therapy, although some endoscopists report rebleeding rates
on medical therapy alone of up to 28% and recommend
endoscopic hemostasis for this stigma (5). Endoscopic treat-
ment of minor stigmata of ulcer hemorrhage (flat spots or
gray slough) or clean ulcer bases is not recommended be-
cause outcomes do not improve and may worsen (1–6). For
all patients with ulcer hemorrhage, biopsy for H. pylori and
subsequent eradication of infection, early refeeding, treat-
ment with high-dose proton pump inhibitors (PPIs) to heal
ulcers, and counseling about the dangers of subsequent
nonsteroidal anti-inflammatory drugs or aspirin ingestion
are highly recommended also (4).
Many types of endoscopic hemostasis techniques for
treatment of nonvariceal bleeding lesions have been devel-
oped and studied over the last 25 yr (1). The major thermal
types include lasers, monopolar electrocoagulation, argon
plasma coagulator, bipolar probes, and heater probe. The
former two are now rarely used for emergency hemostasis
because of inconvenience, efficacy, or safety concerns. The
argon plasma coagulator does not coagulate through blood
well and has superficial coagulation, which renders treat-
ment of ulcers with larger underlying vessels impractical.
Injection techniques are with epinephrine (usually
1:10,000), sclerosants, clotting factors, or cyanoacrylate.
Worldwide, emergency hemostasis with epinephrine (alone
or in combination with sclerosants, thermal, or mechanical
therapy) is probably the most common technique for emer-
gency ulcer hemostasis. Topical methods such as spraying
of vasoactive drugs, tissue glues, clotting factors, or ferro-
magnetic tamponade onto ulcers are safe but not effective
for arterial hemostasis and therefore rarely used to treat
ulcers with major stigmata of hemorrhage. Mechanical tech-
niques such as hemoclips, endoloops, rubber bands, or su-
tures have been applied to both variceal and nonvariceal
lesions (1). For emergency endoscopic hemostasis of ulcers
with major stigmata of hemorrhage, most endoscopists rely
upon their own training and experience, using techniques
that are available on their emergency hemostasis carts, and
catheters or probes that are easily applied, effective, and safe
(1–8).
Thermal contact probes such as the heater probe or mul-
tipolar probes have been marketed in most countries for
more than 20 yr (1, 3, 9). These can be applied en face or
tangentially in almost all peptic ulcers with major stigmata
of hemorrhage. Target irrigation, suctioning, and tamponade
of the bleeding point help the endoscopist localize the stig-
mata in the ulcer and facilitate endoscopic treatment (1, 9).
In the laboratory, coaptive coagulation or welding the walls
of the vessel together can be achieved for arteries up to 2
mm in diameter, when blood flow is first interrupted by firm
tamponade and then at least 150 J of thermal energy (or
W/s) are applied (1, 2, 7). Large diameter probes and slow
coagulation give the most consistent results in the laboratory
and clinically for coaptation of lesions with arterial bleeding
(1, 2, 7, 9). Based upon the histopathological studies of
Swain et al. (8) and others (1), most peptic ulcers with major
stigmata of hemorrhage have arteries smaller than 2 mm in
diameter, and therefore are amenable to coaptive coagula-
tion with large heater or multipolar probes.
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